Reports
Sale
Chronic Urticaria Market Size, Research, Analysis: By Therapeutic Class: Antihistamines, H-2 Blockers, Antidepressants, Monoclonal Antibodies, Others; By Route of Administration: Oral, Parenteral, Others; By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others; Regional Analysis; Supplier Landscape; 2024-2032
Chronic Urticaria Market Outlook
The chronic urticaria market size is expected to grow at a CAGR of 8.7% during the forecast period of 2024-2032, driven by the rising development of novel drugs to mitigate the incidence of chronic urticaria across the globe.
Chronic Urticaria: Introduction
Urticaria, commonly known as hives, is the presence of itchy, red bumps (welts) on the skin. These welts can be small, ring shaped, or irregularly shaped structures. If they persist for six weeks or longer, it can be declared as chronic urticaria. Although it is not life threatening, chronic urticaria can be a symptom of health issues like type 1 diabetes, lupus, rheumatoid arthritis, an autoimmune disorder, or celiac disease.
Urticaria is generally caused by an allergic reaction. It can be caused by allergens like pollen, food, medications, animal dander, or insect bites. People with high stress, illnesses, and other infections might also suffer from it. The body starts releasing histamines in the blood when it goes through an allergic reaction. Histamines can cause swelling and itching, among other symptoms. It is mostly treated with the help of antihistamines, antidepressants, monoclonal antibodies, and H2 blockers.
Chronic Urticaria Market Analysis
Urticaria is triggered by histamine release in the body. They are produced when the body attempts to fight against a foreign intruder or infection. Certain type of drugs, including antibiotics or non-steroidal anti-inflammatory drugs (NSAIDs), can also trigger the condition.
In addition, the prevalence of food preservatives, alcohol or tobacco consumption in modern lifestyle have also contributed to high urticaria cases. As the prevalence of the condition continues to grow, it will also lead to chronic urticaria market growth in the upcoming years.
Chronic urticaria is a prevalent disorder affecting at least 1% of the world population, mostly young and middle-aged women. There are two types of chronic urticaria, chronic spontaneous urticaria and chronic inducible urticaria. Out of the two, chronic spontaneous urticaria accounts for approximately 50-75 % of the total cases. It is a complex disorder that is not triggered by environmental and physical factors. With high incidence, its treatment is key area interest in scientists.
Several drugs for chronic spontaneous urticaria are under clinical trials with results awaited in 2024. Amgen’s tezepelumab, Allakos’s lirentelimab, and Celldex Therapeutics’s barzolvolimab are some of the most prominent ones. Sanofi and Regeneron are working on urticaria triggered by low temperature called Dupilumab. The drug is currently under Phase III trial with results expected to be out in 2024. The chronic urticaria market value is anticipated to rise in the coming years considering the upcoming drug approvals that can be extremely worthy to decrease the severity of the illness.
Chronic Urticaria Market Segmentation
Market Breakup by Therapeutic Class
- Antihistamines
- H-2 Blockers
- Antidepressants
- Monoclonal Antibodies
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Others
Market Breakup by Region-7MM
- United States
- EU-4 and the United Kingdom
- Japan
Chronic Urticaria Market Overview
More than 500,000 people in the United States alone are estimated to chronic urticaria. Therefore, majority of the chronic urticaria market share has been dominated by the North American region in the historical period. On contrary, as per recent trends, the North American region has lowest prevalence of the disease. This can be attributed to the existence of an effective healthcare and pharmaceutical system that leaps in innovation and scientific development to mitigate the disease.
Chronic urticaria market size is expected to grow further in the Latin American and Asian region, owing to high prevalence of cases in the future. The chances of women getting affected is greater than men, whereas for children below 15 years of age, there is not much gender associated difference. With the influx of government grants and foreign investments along with high-end technical advancements, the market can grow considerably in the coming years.
Chronic Urticaria Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Johnson & Johnson Private Limited
- Novartis AG
- Amneal Pharmaceuticals, Inc.
- Pfizer Inc.
- Mylan N.V
- GlaxoSmithKline plc
- Merck & Co., Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Therapeutic Class |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region -7MM |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1. Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2. Executive Summary
3. Chronic Urticaria Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4. Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5. Chronic Urticaria Epidemiology Analysis-7MM
5.1 Epidemiology Overview (2016-2031)
5.2 United States Chronic Urticaria Epidemiology (2016-2031)
5.3 EU-4 and United Kingdom Chronic Urticaria Epidemiology (2016-2031)
5.4 Japan Chronic Urticaria Epidemiology (2016-2031)
6. Chronic Urticaria Market Overview
6.1 Chronic Urticaria Market Historical Value (2017-2023)
6.2 Chronic Urticaria Market Forecast Value (2024-2032)
7. Chronic Urticaria Market Landscape
7.1 Chronic Urticaria Market: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Chronic Urticaria Market: Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by Route of Administration
8. Chronic Urticaria Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9. Cost of Treatment
10. Chronic Urticaria Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11. Chronic Urticaria Market Segmentation -7MM
11.1 Chronic Urticaria Market by Therapeutic Class
11.1.1 Market Overview
11.1.2 Antihistamines
11.1.3 H-2 Blockers
11.1.4 Antidepressants
11.1.5 Monoclonal Antibodies
11.1.6 Others
11.2 Chronic Urticaria Market by Route of Administration
11.2.1 Market Overview
11.2.2 Oral
11.2.3 Parenteral
11.2.4 Others
11.3 Chronic Urticaria Market by Distribution Channel
11.3.1 Market Overview
11.3.2 Hospital Pharmacy
11.3.3 Online Pharmacy
11.3.4 Retail Pharmacy
11.3.5 Others
11.4 Chronic Urticaria Market by Region -7MM
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.4 Japan
12. United States Chronic Urticaria Market
12.1 U.S. Chronic Urticaria Market Historical Size (2017-2023)
12.2 U.S. Chronic Urticaria Market Forecast Size (2024-2032)
12.3 Market Size by Therapeutic Class
13. EU-5 and the United Kingdom Chronic Urticaria Market
13.1 EU-5 and the United Kingdom Chronic Urticaria Market Historical Size (2017-2023)
13.2 EU-5 and the United Kingdom Chronic Urticaria Market Forecast Size (2024-2032)
13.3 Market Size by Therapeutic Class
14. Japan Chronic Urticaria Market
14.1 Japan Chronic Urticaria Market Historical Size (2017-2023)
14.2 Japan Chronic Urticaria Market Forecast Size (2024-2032)
14.3 Market Size by Therapeutic Class
15. Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16. Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17. Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18. Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19. Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20. Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21. Supplier Landscape
21.1 Johnson & Johnson Private Limited
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Novartis AG
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Amneal Pharmaceuticals, Inc.
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Pfizer Inc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Mylan N.V
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 GlaxoSmithKline plc
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Merck & Co., Inc.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
22. Chronic Urticaria Market - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23. Key Opinion Leaders (KOL) Insights (Additional Insight)
24. Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25. Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 8.7% during the forecast period of 2024-2032, driven by the vision to alleviate chronic urticaria in patients with the help of efficient drugs.
With the COVID-19 outbreak and other lifestyle changes, the body has got more susceptible to infections and allergens. This has led to a surge in research and development for effective urticaria drugs resulting in market growth.
The incidence of chronic spontaneous urticaria is higher than chronic inducible urticaria, hence, several drugs are under clinical trials for spontaneous urticaria. While North America has held a significant share of the market during the historical period, Asia Pacific region is likely to experience fast growth in the upcoming years.
The major regions of the market include United States, EU-4, the United Kingdom, and Japan. The United States is currently leading the market.
Chronic urticaria can be treated with the help of drugs like antihistamines, H-2 blockers, antidepressants, and monoclonal antibodies, among others.
Chronic urticaria treatments can be oral and/or parenteral, among others.
The distribution channels in the market are hospitals pharmacies, retail pharmacies, and online pharmacies stores, among others.
Key players involved in the market are Johnson & Johnson Private Limited, Amneal Pharmaceuticals, Inc., Pfizer Inc., Mylan N.V, Merck & Co., Inc., GlaxoSmithKline plc, and Novartis AG.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER